Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Erlotinib |
Trade Name | Tarceva |
Synonyms | CP358774 |
Drug Descriptions |
Tarceva (erlotinib) is a first-generation EGFR inhibitor that blocks EGFR signaling, potentially leading to inhibition of tumor growth (PMID: 30069756). Tarceva (erlotinib) is FDA approved for use in patients with non-small cell lung cancer harboring EGFR exon 19 deletions and/or EGFR L858R, and in combination with gemcitabine for patients with locally advanced, unresectable, or metastatic pancreatic cancer (FDA.gov). |
DrugClasses | EGFR Inhibitor (Pan) 62 EGFR Inhibitor 1st gen 3 |
CAS Registry Number | 183321-74-6 |
NCIT ID | C65530 |